Development of biobanks in Africa raises ethical questions related to particular features of African cancer research contexts, such as underresourced health care and research infrastructures and low-average research literacy. This article describes ethical challenges of informed consent, benefit sharing, and stigmatization and proposes navigating these challenges by developing a comprehensive governance framework to ensure African leadership in biobanking research programs in Africa. Biobanking in African Research Recent years have seen increased efforts to capture global genetic diversity in an attempt to ensure that the benefits of genomic innovation filter down to all people around the globe, including Africans. 1,2,3 Efforts such as the Human Heredity and Health in Africa (H3Africa) Consortium 2 and the Bridging Biobanking and Biomedical Research Across Europe and Africa (B3Africa) Consortium 4 are aimed at achieving this diversity, increasingly through the inclusion of African researchers and populations in genomics studies. These initiatives either set up new biobanks or strengthen the capacity of already existing ones. 4,5 Biobanking-the practice of collecting, curating, and archiving biospecimens for research purposes-is one key tool that is available to scientists to accelerate genomic cancer research. A biobank stores large numbers of samples and associated data and makes these resources available for further research. To serve its purpose as a research resource, biobanks are expected to (1) have defined mechanisms for accessing biospecimens, (2) ensure that the use of biospecimens is in accordance with the informed consent of the participants who donated the samples, (3) have policies for biospecimens disposal, and (4) have a benefit sharing plan.